Latest News

 Filter by Provider

Believing in a Bitcoin supercycle doesn't really change how to invest in it.

Here's how pharmaceutical stocks compare to biotech in terms of risk, rewards, and costs.

On a day when the Nasdaq plunged, housing stocks were surprising winners.

Forget the quantum computing pure plays -- Microsoft is in a unique position in this space.

Executives from Healios and SAB Biotherapeutics (NASDAQ:SABS) outlined their approaches to developing scalable biologic therapies during a Chardan discussion focused on complex treatments designed for commercial manufacturing. Healios Chief Financial Officer Rich Kincaid discussed the company’s mul

Architectural specifications and the adoption of electronic locks create multiyear revenue visibility that pricing discipline alone cannot explain.

Both companies are experiencing sales growth but also substantial losses.

Cancellations now stem from clinical failures rather than funding shortages, signaling a healthier market for contract research.

Margin gains from internal brewing are offsetting volume declines, but new high-margin brands will determine if that cushion holds.

The EV maker's operating profit recovered last quarter. But was a one-off bump behind it?

Sun Cruiser surges 60% as gross margins hit highest level since 2017.

Record adjusted net income and improved cost guidance signal production growth ahead.

Management's refusal to chase loan volume with looser terms is the real test of whether cost discipline can sustain earnings growth.

Operational efficiency gains are offsetting cost inflation, underpinning the company's ability to sustain margin expansion.

The beverage and snacks titan has been the fast-food purveyor's exclusive beverage partner for decades.

Production ramps create near-term cost pressure, but management sees a clear path to 18% operating margins by decade's end.

Media revenue jumped over 10% as synergy gains drive margin expansion.

HOKA and UGG drive record revenue despite promotional headwinds and logistics disruptions.

Revenue surged 55% as cloud storage demand and AI infrastructure investments accelerated.

The company is converting capital markets infrastructure into high-margin recurring revenue, a structural shift that insulates profitability from trading volatility.

Prelude Therapeutics (NASDAQ:PRLD) outlined progress across three priority programs at a Chardan Capital investor session, emphasizing its recently initiated JAK2 program, an IND-cleared KAT6A degrader for breast cancer and a mutant calreticulin, or mCALR, program for myeloproliferative neoplasms.

Cost discipline and moderating capital spending are freeing up cash flow for shareholder returns.

Pricing power and operational discipline held margins steady even as sales flatlined, signaling resilience beyond the current channel turbulence.

Higher charge-offs and lower earnings guidance offset the strategic wins from new funding partnerships and loan retention.

Wood's Ark Invest is building back its exposure to Netflix.

Management closed nine branches to boost annual pre-tax income by $2.3M–$2.7M.

A $1.4 billion cost headwind this year tests whether innovation-backed pricing can sustain margin protection without sacrificing volume.

Mullen Group (TSE:MTL) said its third-quarter operating performance was among its strongest to date, citing the resilience of its diversified business model, a strong balance sheet and improving returns in selected industrial markets. Management also said it remains cautious about committing capital

Xtract One Technologies (TSE:XTRA) reported record fiscal 2026 revenue as demand grew for its security-screening products across education, healthcare, commercial and entertainment markets, while operating expenses rose at a slower rate than sales. For the year, revenue increased 108% to C$28.8 mil

Ermenegildo Zegna (NYSE:ZGN) reported third-quarter 2026 revenue of €434 million, up 8% organically from the prior-year period, as direct-to-consumer growth across all regions offset pressure in parts of its wholesale operations and a more difficult consumer backdrop in Greater China for Thom Browne

Waste Connections (NYSE:WCN) reported third-quarter results that exceeded its expectations and raised its full-year 2026 outlook, citing pricing gains, improving landfill activity, acquisition contributions and commodity-related revenue growth. Third-quarter revenue rose 7.3% from a year earlier to

Wyndham Hotels & Resorts (NYSE:WH) reported third-quarter results marked by stronger-than-expected U.S. revenue per available room growth, higher franchise fee revenue and an increased full-year outlook for several financial measures. Chief Executive Officer Geoff Ballotti said comparable adjusted

Valero Energy (NYSE:VLO) reported sharply higher third-quarter 2026 earnings as strong refining conditions, high utilization rates and improved renewable diesel profitability lifted results across its operating segments. Net income attributable to Valero stockholders totaled $6.8 billion, or $23.89

Columbia Banking System (NASDAQ:COLB) reported third-quarter 2026 earnings per share of $0.78 and operating EPS of $0.82, as the regional bank cited balance-sheet optimization, customer deposit growth and expense discipline as drivers of improved profitability. Operating pre-provision net revenue r

United Rentals (NYSE:URI) reported record third-quarter results and raised its full-year outlook, citing sustained demand from large projects across construction, infrastructure, energy, manufacturing and data-center-related end markets. Total revenue rose 16% year over year to $4.9 billion during

Adobe trades at a fraction of Arista's valuation multiple, while Arista boasts nearly double the profit margin -- a classic comparison between value and growth.

Here's why this popular Canadian real estate stock is one of the best picks for retirees inside their TFSAs.

Tupperware integration drives 43% revenue growth as Jafra faces headwinds.

Airbnb produces higher margins, but analysts expect DoorDash to post higher earnings growth.

Sienna Senior Living pays $0.078 a share every month, about a 4.8% yield. See Q2 2026 growth, payout safety and the risks before you invest.

Record graduate loan originations surge 119% as SLM navigates capital market headwinds.

Alphabet's AI business is booming, but the search business is not out of the woods just yet.

Is Tesla worth the price for SpaceX?

They have different valuations, while profitability and cash generation also tell a starkly different story.

Here’s why Telus’s new dividend looks more sustainable and why the cut could make the stock a better long-term investment.

Supported by strong fundamentals, favourable industry tailwinds, and promising growth prospects, Savaria offers long-term investors the potential for capital appreciation alongside a steady stream of monthly dividend income.

BCE’s Q3 2026 results will reveal whether its shift from dividend growth to debt reduction is delivering meaningful financial progress.

NIM expands as American National integration completes, driving growth momentum.

Union Pacific (NYSE:UNP) reported record third-quarter financial results as freight volume growth, operating productivity and intermodal demand supported higher revenue and earnings, while elevated diesel prices remained a significant cost headwind. Net income totaled $2.1 billion, and adjusted ear

Vera Therapeutics (NASDAQ:VERA) reported final efficacy results from its Phase III ORIGIN trial evaluating atacicept, marketed as TRUTAKNA, in adults with IgA nephropathy. The company presented the data at the American Society of Nephrology’s Kidney Week meeting in Denver, alongside publication in T